A number of investment brokers have recently updated their price targets on shares of Biocept, Inc. (BIOC). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

08/19/2015 – H.C. Wainwright began new coverage on Biocept, Inc. giving the company a “buy” rating. They now have a USD 4 price target on the stock.

05/12/2015 – Biocept, Inc. was downgraded to “hold” by analysts at Zacks.

01/21/2015 – Biocept, Inc. had its “buy” rating reiterated by analysts at Aegis Capital. They now have a USD 16 price target on the stock.

05/01/2014 – Feltl & Co. began new coverage on Biocept, Inc. giving the company a “strong-buy” rating.

The share price of Biocept, Inc. (BIOC) was down -11.25% during the last day of trading, with a day high of 0.92. 807945 shares were traded during the last session.

The stock’s 50 day moving average is 1.24 and its 200 day moving average is 1.53. The stock’s market capitalization is 15.25M. Biocept, Inc. has a 52-week low of 0.81 and a 52-week high of 3.70.

View other investors thoughts on Biocept, Inc. with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.